Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,918,112
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.69
  • Price/Sales 4.93
  • Price/Cash Flow 14.70
  • Price/Book 6.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 2.03
  • Number of Estimates 8
  • High Estimate 2.09
  • Low Estimate 2.00
  • Prior Year 1.90
  • Growth Rate Est. (year over year) +6.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.44 +6.40%
on 09/04/18
142.14 -0.11%
on 09/20/18
+5.10 (+3.73%)
since 08/20/18
3-Month
120.11 +18.21%
on 07/02/18
142.14 -0.11%
on 09/20/18
+19.94 (+16.34%)
since 06/20/18
52-Week
118.62 +19.69%
on 05/29/18
148.32 -4.27%
on 01/17/18
+8.76 (+6.58%)
since 09/20/17

Most Recent Stories

More News
Johnson & Johnson Vision Showcases Latest Clinical Data and Eye Care Solutions at the ESCRS 2018 Annual Meeting

- Latest clinical data builds on the wealth of evidence supporting the safety, efficacy and overall benefits of TECNIS Symfony(R) IOLs for cataract patients

JNJ : 141.98 (+1.08%)
Muscle Relaxant Drugs - Global Markets to 2024: Abbott Labs, Medtronic, Johnson & Johnson, Endo Pharma, and more are Profiled - ResearchAndMarkets.com

The "Muscle Relaxants Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

ABT : 68.79 (+0.42%)
JNJ : 141.98 (+1.08%)
MDT : 97.48 (+1.06%)
CIO Summit: The CIO's Role in Advancing Customer-led Business Transformation Will Drive the Dialogue at HMG Strategy's Upcoming Greenwich CIO Conference

As company leaders look to transform their businesses to better attune to the preferences and needs of its customers, CIOs and technology executives play a critical role in identifying how technology can...

IBM : 151.15 (+1.40%)
JNJ : 141.98 (+1.08%)
PRGO : 73.90 (+0.78%)
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter results. Joseph J. Wolk, Executive Vice President,...

JNJ : 141.98 (+1.08%)
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

JNJ : 141.98 (+1.08%)
MRK : 70.78 (+1.14%)
LLY : 106.07 (+0.31%)
PFE : 43.75 (+1.13%)
Aduro's Cancer Arm & Strong Collaborations Boost Growth

Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

JNJ : 141.98 (+1.08%)
NVS : 85.97 (+1.26%)
ADRO : 6.30 (-1.56%)
BMY : 61.75 (+1.56%)
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of erdafitinib...

JNJ : 141.98 (+1.08%)
Cerus Endovascular Strengthens Board of Directors with Appointment of John T. Kilcoyne

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and...

JNJ : 141.98 (+1.08%)
Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors

-- Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors

OSUR : 15.46 (-0.39%)
JNJ : 141.98 (+1.08%)
TYME : 2.65 (-1.12%)
CISCRP Releases New Video on Initiative to Improve Diversity in Clinical Research

The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization, announces a new video featuring an innovative program to increase awareness and...

JNJ : 141.98 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 143.17
1st Resistance Point 142.58
Last Price 141.98
1st Support Level 140.95
2nd Support Level 139.91

See More

52-Week High 148.32
Last Price 141.98
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar